JP4545196B2 - 有糸分裂キネシン阻害剤 - Google Patents

有糸分裂キネシン阻害剤 Download PDF

Info

Publication number
JP4545196B2
JP4545196B2 JP2007552192A JP2007552192A JP4545196B2 JP 4545196 B2 JP4545196 B2 JP 4545196B2 JP 2007552192 A JP2007552192 A JP 2007552192A JP 2007552192 A JP2007552192 A JP 2007552192A JP 4545196 B2 JP4545196 B2 JP 4545196B2
Authority
JP
Japan
Prior art keywords
alkyl
compounds
aryl
cycloalkyl
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007552192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008527038A (ja
JP2008527038A5 (https=
Inventor
コールマン，ポール・ジエイ
ハートマン，ジヨージ・デイー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2008527038A publication Critical patent/JP2008527038A/ja
Publication of JP2008527038A5 publication Critical patent/JP2008527038A5/ja
Application granted granted Critical
Publication of JP4545196B2 publication Critical patent/JP4545196B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007552192A 2005-01-19 2006-01-13 有糸分裂キネシン阻害剤 Expired - Fee Related JP4545196B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64493305P 2005-01-19 2005-01-19
PCT/US2006/001364 WO2006078574A2 (en) 2005-01-19 2006-01-13 Mitotic kinesin inhibitors

Publications (3)

Publication Number Publication Date
JP2008527038A JP2008527038A (ja) 2008-07-24
JP2008527038A5 JP2008527038A5 (https=) 2009-03-05
JP4545196B2 true JP4545196B2 (ja) 2010-09-15

Family

ID=36692758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552192A Expired - Fee Related JP4545196B2 (ja) 2005-01-19 2006-01-13 有糸分裂キネシン阻害剤

Country Status (7)

Country Link
US (1) US20080102068A1 (https=)
EP (1) EP1856128A4 (https=)
JP (1) JP4545196B2 (https=)
CN (1) CN101107253A (https=)
AU (1) AU2006206738A1 (https=)
CA (1) CA2595127A1 (https=)
WO (1) WO2006078574A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
NZ602089A (en) 2010-02-17 2014-05-30 Takeda Pharmaceutical Heterocyclic compounds having cell division cycle 7 inhibitory activity
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物
EP2558452A2 (en) * 2010-04-15 2013-02-20 Novartis AG Oxazole and thiazole compounds as ksp inhibitors
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
MA46228A (fr) * 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
AU2020409437A1 (en) * 2019-12-18 2022-07-14 Universite De Montreal Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327224T1 (de) * 1999-10-27 2006-06-15 Cytokinetics Inc Chinazolinone benutzende verfahren und zusammenstellungen
AU2002364128B2 (en) * 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7378411B2 (en) * 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
US7262187B2 (en) * 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
US20050107404A1 (en) * 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
CA2489562A1 (en) * 2002-07-08 2004-01-15 Merck & Co., Inc. Mitotic kinesin binding site
WO2004064741A2 (en) * 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用

Also Published As

Publication number Publication date
AU2006206738A1 (en) 2006-07-27
JP2008527038A (ja) 2008-07-24
WO2006078574A3 (en) 2007-03-22
CN101107253A (zh) 2008-01-16
US20080102068A1 (en) 2008-05-01
CA2595127A1 (en) 2006-07-27
WO2006078574A2 (en) 2006-07-27
EP1856128A2 (en) 2007-11-21
EP1856128A4 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
JP4545196B2 (ja) 有糸分裂キネシン阻害剤
CN101155583B (zh) 有丝分裂驱动蛋白的抑制剂
JP2006516140A (ja) 有糸分裂キネシン阻害剤
JP2006516142A (ja) 有糸分裂キネシン阻害剤
JP2007518711A (ja) 有糸分裂キネシン阻害剤
JP2008535803A (ja) 有糸分裂キネシン阻害剤
CN101084194A (zh) 有丝分裂驱动蛋白抑制剂
US7595337B2 (en) Mitotic kinesin inhibitors
JP2008527039A (ja) 有糸分裂キネシン阻害剤としてのフッ素化アミノアルキル−４−オキソ−３，４−ジヒドロピリド［３，４−ｄ］ピリジン
JP2008527041A (ja) 有糸分裂キネシン阻害剤
JP2008510013A (ja) 有糸分裂キネシン阻害剤
JP2008505089A (ja) 有糸分裂キネシン阻害剤
CN1980938B (zh) 有丝分裂驱动蛋白抑制剂
JP2008505094A (ja) 有糸分裂キネシン阻害剤
US20070149553A1 (en) Mitotic kinesin inhibitors
JP2008510012A (ja) 有糸分裂キネシン阻害剤
JP2008533144A (ja) 有糸分裂キネシン阻害剤
JP2007530545A (ja) 有糸分裂キネシン阻害剤
JP2008505090A (ja) 有糸分裂キネシン阻害剤のプロドラッグ
CN1980663A (zh) 有丝分裂驱动蛋白抑制剂的前体药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091013

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100608

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100629

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees